The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
One, twenty years ago I was the chairman of the government affairs committee of the American Society for Clinical Pharmacology and Therapeutics; under that role my committee was successful lobbying for approval new investigational drugs for possible treatment of AIDS. We were successful in getting the...
The announcement the new trial comparing Lipitor to Crestor is interesting but not unexpected. It is timed to end near the end of lipitor's patent. A win- which is likely- will certainly help AZN sell their drug against the much cheaper generic lipitor.
Lipitor is the dominant statin on the market and has an indication for reducing the risk of heart attack and stroke. Crestor is more potent than Lipitor, but, because it was approved later, has less data to show for and no indication for lowering the risk of clinical events. Moreover, Zocor (Simvastatin)...
Impressive data on Ranexa in HGBA1c. The result of a decrease of 0.64 vs baseline and 0.43 vs placebo are at first glance underwhelming. But a closer looks shows that the results are realy quite impressive
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
Apparently doctors aren't quite as easily manipulated by pharma as we all thought. Despite a vigorous marketing effort, Bidil was seen by cardiologist as what it is- an expensive combination of two generics and was not used- even after insurance companies started to pay for it.
My expertise in the clinical research of Torcetrapib and reports presented at the latest American College of Cardiology meetings made me conclude that the failure of Torcetrapib in rendering clinical benefits were related to intrinsic problems of the drug which effected the nature of the HDL which...
Those like myself who have more extensive knowledge on the rational used by the FDA to reject the approval of Rimonabant and know the differences between Rimonabant and Taranabant do not believe that there is an error in judgment by Merck in developing their new cannabinoid receptor antagonist. This...